STTCOMP ACW, TA Long Actinogen Medical is an ASX-listed...

STTCOMP ACW, TA Long
Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes.
Market Cap: $38m / Cash: $5.5m

Detailed Description/Catalyst
Volume spike in Nov 17 looks to be capitulation of holders. This was then followed up by another volume spike in Feb 18 which looks like new entrants to the FA story that is about to unfold here.
Volume has also generally increased from 2017 vs. 2018 as indicated in the purple lines.

Tested 3.9-4.0 cents several times over the past 2 years and this is looking to be a bottom.

The first pennant stretches over 2 years and we are trading just below breakout.
The second pennant looks to have started at the beginning of Feb 18 (the second volume spike mentioned above) and is looking to have 1 month max left until breakout.

Charts I'm looking at are below:

FA tip to follow...
***DISCLAIMER: Don’t take as financial advice as I am not qualified/licenced to give it.***